Soltis Investment Advisors LLC Acquires New Shares in Humana Inc. $HUM

Soltis Investment Advisors LLC purchased a new stake in shares of Humana Inc. (NYSE:HUM) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,236 shares of the insurance provider’s stock, valued at approximately $471,000.

Several other institutional investors have also recently bought and sold shares of HUM. BlackRock Inc. bought a new stake in Humana during the second quarter worth $4,138,160,000. Pzena Investment Management LLC purchased a new position in Humana in the second quarter worth $1,749,014,000. Assenagon Asset Management S.A. grew its stake in Humana by 20,126.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider’s stock valued at $479,053,000 after purchasing an additional 1,249,272 shares during the period. Legal & General Group Plc bought a new position in Humana in the 2nd quarter valued at $329,760,000. Finally, Barrow Hanley Mewhinney & Strauss LLC bought a new position in Humana in the 2nd quarter valued at $314,922,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Analyst Ratings Changes

HUM has been the topic of a number of recent analyst reports. Monness Crespi & Hardt upgraded Humana to a “buy” rating in a research note on Friday, October 9th. Leerink Partners upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $513.00 price target for the company in a research report on Thursday, July 30th. Evercore upgraded shares of Humana from an “in-line” rating to an “outperform” rating and set a $480.00 price objective for the company in a report on Wednesday, July 29th. Wall Street Zen lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Wells Fargo & Company raised shares of Humana from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $227.00 to $502.00 in a research report on Monday, July 13th. Twenty-one research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Humana presently has a consensus rating of “Moderate Buy” and an average target price of $453.30.

Humana Price Performance

Humana stock opened at $414.04 on Monday. Humana Inc. has a 52 week low of $163.11 and a 52 week high of $456.50. The business has a 50-day simple moving average of $400.92 and a 200 day simple moving average of $308.70. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.62. The stock has a market cap of $49.72 billion, a price-to-earnings ratio of 39.17, a PEG ratio of 2.55 and a beta of 0.74.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Investors of record on Thursday, December 24th will be given a $0.8850 dividend. This represents a $3.54 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Thursday, December 24th. Humana’s dividend payout ratio is 33.49%.

Humana Company Profile

Humana Inc is a health and well-being company that provides insurance products and health care services in the United States and Puerto Rico. The company’s primary business is government-sponsored health coverage, particularly Medicare Advantage plans for older adults, along with Medicare prescription drug plans, Medicaid coverage and certain commercial health insurance products.

Humana also operates CenterWell, its health care services platform focused on older adults. CenterWell includes primary care clinics, home health services and pharmacy services, with an emphasis on coordinated care, chronic-condition management and helping members receive care in lower-cost settings.

Founded in 1961 as a nursing-home company, Humana expanded into hospital operations before shifting its focus toward health insurance and related services.